{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:02:27Z","timestamp":1750478547405,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This report details the reactivation of immune checkpoint inhibitor (ICI)-related autoimmune hepatitis triggered by stereotactic body radiation therapy (SBRT) in a\u00a055-year-old male with hilar cholangiocellular carcinoma. Initially diagnosed in December 2021, the patient underwent successful resection and subsequent adjuvant therapy. Despite stable disease following chemotherapy augmented with durvalumab, he developed grade\u00a03 acute hepatitis after seven cycles of durvalumab. Following a\u00a0brief prednisolone regimen and normalization of liver tests, SBRT targeting para-aortic lymph nodes was initiated. Remarkably, severe hepatitis reoccurred 7\u00a0days after starting SBRT, 88\u00a0days following the last durvalumab infusion, necessitating resumed and escalated prednisolone treatment. Another course of SBRT for a\u00a0newly diagnosed metastatic liver lesion was administered in September 2023, with ongoing prednisolone adjustment. By February 2024, liver tests normalized, but subsequent radiological assessments indicated tumor progression, leading to the reintroduction of chemotherapy. This case underscores the potential of SBRT for activating severe immune-mediated hepatotoxicity in patients treated with ICIs, highlighting the need for careful monitoring and management of such patients. Further, this report highlights the possible survival benefit of the strategic application of SBRT in addition to systematic treatment in recurrent and metastatic cholangiocellular carcinoma.<\/jats:p>","DOI":"10.1007\/s00066-024-02361-0","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:15:17Z","timestamp":1738703717000},"page":"752-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential radiotherapy-related reactivation of immune checkpoint inhibitor hepatitis"],"prefix":"10.1007","volume":"201","author":[{"given":"Kakharman","family":"Yesmembetov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cennet","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Murad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Luise","family":"Berres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"von Websky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Vondran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Bruners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-1996","authenticated-orcid":false,"given":"Ahmed Allam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"S5","key":"2361_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","volume":"41","author":"ML Disis","year":"2014","unstructured":"Disis\u00a0ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41(S5):S3\u201313","journal-title":"Semin Oncol"},{"key":"2361_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"DY Oh","year":"2022","unstructured":"Oh\u00a0DY, Ruth\u00a0A, Qin\u00a0S, Chen\u00a0LT, Okusaka\u00a0T, Vogel\u00a0A et\u00a0al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"12","key":"2361_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen\u00a0J, Obeid\u00a0M, Spain\u00a0L, Carbonnel\u00a0F, Wang\u00a0Y, Robert\u00a0C et\u00a0al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"issue":"9","key":"2361_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","volume":"23","author":"K Reynolds","year":"2018","unstructured":"Reynolds\u00a0K, Thomas\u00a0M, Dougan\u00a0M (2018) Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 23(9):991\u2013997","journal-title":"Oncologist"},{"key":"2361_CR5","doi-asserted-by":"crossref","unstructured":"Hercun J, Vincent C, Bilodeau M, Lapierre P Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology. www.frontiersin.org. Accessed 13 June 2024","DOI":"10.3389\/fimmu.2022.907591"},{"issue":"9","key":"2361_CR6","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.4049\/jimmunol.166.9.5430","volume":"166","author":"P Bertolino","year":"2001","unstructured":"Bertolino\u00a0P, Bowen\u00a0DG, McCaughan\u00a0GW, Fazekas de St. Groth\u00a0B (2001) Antigen-specific primary activation of CD8+ T\u00a0cells within the liver. J\u00a0Immunol 166(9):5430\u20135438","journal-title":"J Immunol"},{"key":"2361_CR7","doi-asserted-by":"crossref","unstructured":"Zhang Z, Liu X, Chen D, Yu J (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 7(1) (https:\/\/pubmed.ncbi.nlm.nih.gov\/35906199\/)","DOI":"10.1038\/s41392-022-01102-y"},{"key":"2361_CR8","doi-asserted-by":"crossref","unstructured":"McKay MJ, Foster R (2021) Radiation recall reactions: An oncologic enigma. Crit Rev Oncol Hematol 168: ([cited 2024 Jun 12]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34808375\/)","DOI":"10.1016\/j.critrevonc.2021.103527"},{"key":"2361_CR9","doi-asserted-by":"crossref","unstructured":"Yigit E, Guven DC, Aksoy S, Yazici G (2021) Radiation recall dermatitis in patients treated with immune checkpoint inhibitors: a\u00a0case report and literature review. Cureus 13(6) (https:\/\/pubmed.ncbi.nlm.nih.gov\/34277173\/)","DOI":"10.7759\/cureus.15548"},{"issue":"1","key":"2361_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-020-01718-3","volume":"18","author":"F Teng","year":"2020","unstructured":"Teng\u00a0F, Li\u00a0M, Yu\u00a0J (2020) Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med 18(1):1\u20138. https:\/\/doi.org\/10.1186\/s12916-020-01718-3","journal-title":"BMC Med"},{"key":"2361_CR11","doi-asserted-by":"crossref","unstructured":"Jan PR, Chang JWC, Wu CE (2022) Radiation recall pneumonitis: a\u00a0rare syndrome that should be recognized. Cancers 14(19) (https:\/\/pubmed.ncbi.nlm.nih.gov\/36230564\/)","DOI":"10.3390\/cancers14194642"},{"issue":"1","key":"2361_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2022.07.021","volume":"115","author":"M Qiang","year":"2023","unstructured":"Qiang\u00a0M, Chen\u00a0X (2023) Radiation recall mucositis in immunotherapy: a\u00a0road we\u2019ve traveled. Int J Radiat Oncol Biol Phys 115(1):10\u201311","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2361_CR13","doi-asserted-by":"crossref","unstructured":"Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O et\u00a0al (2022) Immunotherapy recall: chemoradiation-induced reactivation of immune checkpoint inhibitor nephritis. JCO Precis Oncol 6(6) (https:\/\/pubmed.ncbi.nlm.nih.gov\/35952321\/)","DOI":"10.1200\/PO.22.00049"},{"issue":"5","key":"2361_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ijrobp.2024.01.002","volume":"118","author":"C Lynch","year":"2024","unstructured":"Lynch\u00a0C, Korpics\u00a0MC, Katipally\u00a0RR, Wu\u00a0T, Bestvina\u00a0CM, Pitroda\u00a0S et\u00a0al (2024) Combined Stereotactic body radiation therapy and immune checkpoint inhibition for liver metastases: safety and outcomes in a\u00a0pooled analysis of 3\u00a0phase\u00a01 trials. Int J Radiat Oncol Biol Phys 118(5):1519\u20131530","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2361_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas\u00a0M, Sundahl\u00a0N, Kruse\u00a0V, Rottey\u00a0S, De Maeseneer\u00a0D, Duprez\u00a0F et\u00a0al (2023) Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase\u00a02 randomized clinical trial. JAMA Oncol 9(9):1205\u20131213","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"2361_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2023.41.4_suppl.141","volume":"41","author":"JF Seligmann","year":"2023","unstructured":"Seligmann\u00a0JF, Kossler\u00a0T, Mauer\u00a0M, Evrard\u00a0S, Gootjes\u00a0EC, Freedman\u00a0J et\u00a0al (2023) Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase\u00a0II study. JCO 41(4_suppl):141\u2013141. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.141","journal-title":"JCO"},{"issue":"1","key":"2361_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08088-w","volume":"21","author":"M Spaas","year":"2021","unstructured":"Spaas\u00a0M, Sundahl\u00a0N, Hulstaert\u00a0E, Kruse\u00a0V, Rottey\u00a0S, De Maeseneer\u00a0D et\u00a0al (2021) Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a\u00a0phase\u00a02, open-label, randomized controlled trial. Bmc Cancer 21(1):1\u201310. https:\/\/doi.org\/10.1186\/s12885-021-08088-w","journal-title":"Bmc Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02361-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:05:53Z","timestamp":1750410353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02361-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Yesmembetov, C.\u00a0Sahin, M.\u00a0Murad, M.-L.\u00a0Berres, A.\u00a0Koch, M.\u00a0von Websky, F.\u00a0Vondran, P.\u00a0Bruners, M.\u00a0Eble, and A.A.\u00a0Mohamed declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}